Back to search

Article

PCSK9 Inhibitors Do Not Increase Cognitive Risk

2026-01-20

Abstract excerpt

<title>Abstract</title> <p>Background Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors are potent lipid-lowering therapies, yet concerns regarding their neurocognitive safety persist amidst conflicting evidence. Methods We applied an integrated approach combining real-world pharmacovigilance, genetic epidemiology, and preclinical models. Disproportionality analysis was performed using FDA Advers...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5af00e42-e32a-5e62-975b-4c62df8215c5
DOI
10.21203/rs.3.rs-8520824/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PCSK9 Inhibitors Do Not Increase Cognitive RiskDOI 10.21203/rs.3.rs-8520824/v1
Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive FunctionSemantic proximity
Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.Semantic proximity
Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug‐Target Mendelian Randomization StudySemantic proximity
<i>PCSK9</i> genetic variants, life-long lowering of LDL-cholesterol and cognition: a large-scale Mendelian randomization studySemantic proximity
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Induced Neurocognitive Disorder: A Pharmacovigilance Study by Analyzing the Data from the U.S. FDA Adverse Event Reporting SystemSemantic proximity
Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.Semantic proximity
PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS).Semantic proximity
Lipid lowering and Alzheimer disease risk: A mendelian randomization study.Semantic proximity
Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic StrokeSemantic proximity
PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.Semantic proximity
The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug TargetingSemantic proximity
LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization StudySemantic proximity
Select a neighboring publication to make it the new centre.